Agendia

Agendia is a precision oncology company headquartered in Irvine, California, committed to providing patients with early stage breast cancer and their physicians the information they need to make the best treatment decisions. The company currently offers two commercially-available genomic profiling tests: MammaPrint®, a 70-gene breast cancer recurrence assay, and BluePrint®, an 80-gene molecular subtyping assay. These tests are supported by high levels of clinical and real-world evidence, aiding in identifying the most effective breast cancer treatment for each patient.

Both MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in pre- and post-operative treatment settings. These assays can be ordered on core biopsies or surgical specimens, thus influencing treatment decisions at various stages of the cancer journey. Agendia's commitment to ongoing research and forging partnerships with innovative companies underpins the development of novel genomic tests and next-generation digital treatment tools, aiming to improve patient outcomes and meet the evolving clinical needs of breast cancer patients and their physicians.

The company's last investment was a $35.00M Private Equity Round from Athyrium Capital Management on 25 July 2018. This financial backing supports Agendia's mission to advance precision oncology and develop cutting-edge solutions for breast cancer treatment. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.